| 1 |
American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis[J]. Crit Care Med, 1992, 20(6): 864-874.
|
| 2 |
Rhodes A, Evans LE, Alhazzani W, et al. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016[J]. Intensive Care Med, 2017, 43(3): 304-377.
|
| 3 |
Singer M, Deutschman CS, Seymour CW, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)[J]. JAMA, 2016, 315(8): 801-810.
|
| 4 |
Wacker C, Prkno A, Brunkhorst FM, et al. Procalcitonin as a diagnostic marker for sepsis: a systematic review and meta-analysis[J]. Lancet Infect Dis, 2013, 13(5): 426-435.
|
| 5 |
Yang Y, Xie J, Guo F, et al. Combination of C-reactive protein, procalcitonin and sepsis-related organ failure score for thediagnosis of sepsis in critical patients[J]. Ann Intensive Care, 2016, 6(1): 51.
|
| 6 |
Oliveira CF, Botoni FA, Oliveira CR, et al. Procalcitonin versus C-reactive protein for guiding antibiotic therapy in sepsis: a randomized trial[J]. Crit Care Med, 2013, 41(10): 2336-2343.
|
| 7 |
Klag T, Cantara G, Sechtem U, et al. Interleukin-6 Kinetics can be Useful for Early Treatment Monitoring of Severe Bacterial Sepsis and Septic Shock[J]. Infect Dis Rep, 2016, 8(1): 6213.
|
| 8 |
Maier M, Wutzler S, Lehnert M, et al. Serum procalcitonin levels in patients with multiple injuries including visceral trauma[J]. J Trauma, 2009, 66(1): 243-249.
|
| 9 |
Shirakawa K, Furusako S, Endo S, et al. New diagnostic marker for sepsis: soluble CD14 subtype[J]. Crit Care, 2004, 8 (Suppl 1): P191.
|
| 10 |
Yaegashi Y, Shirakawa K, Sato N, et al. Evaluation of a newly identified soluble CD14 subtype as a marker for sepsis[J]. J Infect Chemother, 2005, 11(5): 234-238.
|
| 11 |
Liu S, Khemlani LS, Shapiro RA, et al. Expression of CD14 by hepatocytes: upregulation by cytokines during endotoxemia[J]. Infect Immun, 1998, 66(11): 5089-5098.
|
| 12 |
Grunwald U, Krüger C, Westermann J, et al. An enzyme-linked immunosorbent assay for the quantification of solubilized CD14 in biological fluids[J]. J Immunol Methods, 1992, 155(2): 225-232.
|
| 13 |
Landmann R, Zimmerli W, Sansano S, et al. Increased circulating soluble CD14 is associated with high mortality in gram-negative septic shock[J]. J Infect Dis, 1995, 171(3): 639-644.
|
| 14 |
Shirakawa K, Naitou K, Hirose J, et al. The new sepsis marker, sCD14-ST, induction mechanism in the rabbit sepsis models[J]. Crit Care, 2010, 14 (Suppl 2): P19.
|
| 15 |
Shozushima T, Takahashi G, Matsumoto N, et al. Usefulness of presepsin (sCD14-ST) measurements as a marker for the diagnosis and severity of sepsis that satisfied diagnostic criteria of systemic inflammatory response syndrome[J]. J Infect Chemother, 2011, 17(6): 764-769.
|
| 16 |
Nakamura M, Takeuchi T, Naito K, et al. Early elevation of plasma soluble CD14 subtype, a novel biomarker for sepsis, in a rabbit cecal ligation and puncture model[J]. Crit Care, 2008, 12 (Suppl 2): P194.
|
| 17 |
Okamura Y, Yokoi H. Development of a point-of-care assay system for measurement of presepsin (sCD14-ST)[J]. Clin Chim Acta, 2011, 412(23-24): 2157-2161.
|
| 18 |
Behnes M, Bertsch T, Lepiorz D, et al. Diagnostic and prognostic utility of soluble CD 14 subtype (presepsin) for severe sepsis andseptic shock during the first week of intensive care treatment[J]. Crit Care, 2014, 18(5): 507.
|
| 19 |
Ulla M, Pizzolato E, Lucchiari M, et al. Diagnostic and prognostic value of presepsin in the management of sepsis in the emergency department: a multicenter prospective study[J]. Crit Care, 2013, 17(4): R168.
|
| 20 |
Endo S, Suzuki Y, Takahashi G, et al. Usefulness of presepsin in the diagnosis of sepsis in a multicenter prospective study[J]. J Infect Chemother, 2012, 18(6): 891-897.
|
| 21 |
Liu B, Chen YX, Yin Q, et al. Diagnostic value and prognostic evaluation of Presepsin for sepsis in an emergency department[J]. Crit Care, 2013, 17(5): R244.
|
| 22 |
Carpio R, Zapata J, Spanuth E, et al. Utility of presepsin (sCD14-ST) as a diagnostic and prognostic marker of sepsis in the emergency department[J]. Clin Chim Acta, 2015, 450: 169-175.
|
| 23 |
Sato R, Suzuki Y, Sato M, et al. Serum levels of presepsin reflects the APACHE II and SOFA scores inpatients with sepsis[J]. Crit Care, 2013, 17 (Suppl 2): P37.
|
| 24 |
Zheng Z, Jiang L, Ye L, et al. The accuracy of presepsin for the diagnosis of sepsis from SIRS: a systematic review and meta-analysis[J]. Ann Intensive Care, 2015, 5(1): 48.
|
| 25 |
Tong X, Cao Y, Yu M, et al. Presepsin as a diagnostic marker for sepsis: evidence from a bivariate meta-analysis[J]. Ther Clin Risk Manag, 2015, 11: 1027-1033.
|
| 26 |
Masson S, Caironi P, Fanizza C, et al. Circulating presepsin (soluble CD14 subtype) as a marker of host response in patients withsevere sepsis or septic shock: data from the multicenter, randomized ALBIOS trial[J]. Intensive Care Med, 2015, 41(1): 12-20.
|
| 27 |
Endo S, Suzuki Y, Takahashi G, et al. Presepsin as a powerful monitoring tool for the prognosis and treatment of sepsis: a multicenter prospective study[J]. J Infect Chemother, 2014, 20(1): 30-34.
|
| 28 |
Masson S, Caironi P, Spanuth E, et al. Presepsin (soluble CD14 subtype) and procalcitonin levels for mortality prediction in sepsis:data from the Albumin Italian Outcome Sepsis trial[J]. Crit Care, 2014, 18(1): R6.
|
| 29 |
Nakamura Y, Ishikura H, Nishida T, et al. Usefulness of presepsin in the diagnosis of sepsis in acute kidney injury patients[J]. Crit Care, 2013, 17(Suppl 2): P36.
|
| 30 |
Nakamura Y, Ishikura H, Nishida T, et al. Usefulness of presepsin in the diagnosis of sepsis in patients with or without acute kidney injury[J]. BMC Anesthesiol, 2014, 14: 88.
|
| 31 |
Chenevier-Gobeaux C, Trabattoni E, Roelens M, et al. Presepsin (sCD14-ST) in emergency department: the need for adapted threshold values? [J]. Clin Chim Acta, 2014, 27: 34-36.
|